SAPCD2 and neoplasm: In subcutaneous xenografts, silencing SAPCD2 dramatically attenuated the primary growth and tumorigenic abilities of fibrosarcoma cells in vivo, as demonstrated by the reduced tumor volume and tumor weight in the mice inoculated with SAPCD2-silenced fibrosarcoma cells (Figures 3G–I).